Join Oxford Global for the inaugural Advances in Immuno-Oncology USA Congress on the 11th – 12th October 2018 in San Diego, USA. There will be over 350 delegates representing global pharmaceutical organisations, leading biotech companies, and internationally renowned academic institutions.
Hear from leading experts within the immuno-oncology field through over 20 presentations, case studies and panel discussions focuser on the latest innovations in Car-T cell development, patient stratification, and assay developments in the immuno-oncology world.
2 Interactive Streams:
• Development of Immuno-Oncology Therapies – Stream 1 features presentations on the latest developments in T Cell Engagers, cell based functional assays for IDO inhibitors, harnessing novel immune escape mechanisms for cancer therapeutics and toxicities with immuno-oncology therapy
• Translational Immuno-Oncology and Clinical Based Development – Stream 2 addresses talks on the latest patient stratification innovations in immuno-oncology, identifying immunological biomarkers for precision cancer immunotherapy and biomarker based selections in clinical trials.
Register for our live, pre-congress webinar for free today: https://bit.ly/2IrjJXR The Role for TNFR2 in the Tumor Microenvironment Thursday 14th June 2018, 4pm BST
Presented by Russell LaMontagne, Chief Executive Officer: Boston Immune Technologies and Therapeutics Inc
For further information regarding prices and possible discounts, please contact Danielle Dalby on
d.dalby @ oxfordglobal.co.uk or call +44 (0)1865 248 455.